Back to results
US 12,492,256 B2Granted
Methods and compositions for modulating beta chain mediated immunity
AssigneeJanssen Biotech, Inc.
InventorsRajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh, Michael Riis Hansen
Life of this patent
Estimating the term…
Abstract
Anti-Vβ17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
Claims28
An antibody that binds to Vβ17, comprising:
- a heavy chain variable region (VH) comprising a CDR1 comprising the amino acid (i) sequence of SEQ ID NO:
- 1005, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 1006, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 1007;
- and
- (ii) a light chain variable region (VL) comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1020, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 1021, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 1022.
6 more elements
A multispecific antibody, comprising (i) a first binding domain that binds to Vβ17, wherein the first binding domain comprises:
- (a) a heavy chain variable region (VH) comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1005, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 1006, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 1007;
- and
- (b) a light chain variable region (VL) comprising a CDR1 comprising the amino acid sequence of SEQ ID NO:
- 1020, a CDR2 comprising the amino acid sequence of SEQ ID NO:
- 1021, and a CDR3 comprising the amino acid sequence of SEQ ID NO:
- 1022;
- and
- (ii) a second binding domain that binds to a second target that is CD123, BCMA, DLL3, or PSMA.
8 more elements
Dependencies are inferred from the claim text.